论文部分内容阅读
目的:探讨血清诱捕受体3(DcR3)在胃癌患者中的表达及其临床意义。方法:采用酶联免疫吸附试验检测28例胃癌患者血清DcR3水平,并与同期28例正常健康体检人群相对照,分析血清DcR3与胃癌患者的临床病理因素之间关系。结果:胃癌患者血清DcR3[(179.34±69.35)pg/ml]的水平显著高于正常人[(108.56±76.78)pg/ml],差异有统计学意义(P<0.05)。DcR3的表达与胃癌患者的分化程度、淋巴转移和TNM分期相关,与肿瘤大小及浸润深度不相关。结论:DcR3有望成为一项全新的肿瘤标志物,为胃癌的早期诊断、TNM分期及预后判断提供新的理论依据,并进一步指导胃癌治疗,提高胃癌的诊断水平及治疗效果。
Objective: To investigate the expression of serum trapping receptor 3 (DcR3) in gastric cancer and its clinical significance. Methods: The serum levels of DcR3 in 28 patients with gastric cancer were detected by enzyme-linked immunosorbent assay (ELISA), and compared with 28 healthy controls in the same period. The relationship between serum DcR3 and clinicopathological factors was analyzed. Results: The level of serum DcR3 [(179.34 ± 69.35) pg / ml] in gastric cancer patients was significantly higher than that in normal people [(108.56 ± 76.78) pg / ml], the difference was statistically significant (P <0.05). The expression of DcR3 was correlated with the degree of differentiation, lymphatic metastasis and TNM stage in gastric cancer patients, but not with tumor size and depth of invasion. Conclusion: DcR3 is expected to become a new tumor marker, providing a new theoretical basis for the early diagnosis of gastric cancer, TNM staging and prognosis, and further guide the treatment of gastric cancer and improve the diagnosis of gastric cancer and treatment.